Viridian Therapeutics (VRDN) announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 175,000 shares of the company’s common stock to one new employee on July 1, 2025. The Inducement Grant has been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to the individual entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Stockholders Approve Key Proposals
- Viridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
- Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
- Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
- Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating